Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
Hayleigh Collins - Director and Head, Investor Relations
Sean Nolan - Chief Executive Officer
Sukumar Nagendran - President and Head, R&D
Kamran Alam - Chief Financial Officer
Conference Call Participants
Kristen Kluska - Cantor Fitzgerald
Chris Raymond - Piper Sandler
Whitney Ijem - Canaccord Genuity
Salveen Richter - Goldman Sachs
Gil Blum - Needham & Co.
Maury Raycroft - Jefferies
Jack Allen - Baird
Joon Lee - Truist Securities
Silvan Tuerkcan - Citizens JMP
Keith Tapper - BMO Capital Markets
Operator
Greetings. And welcome to the Taysha Gene Therapies’ Third Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. [Operator Instructions]
It is now my pleasure to introduce Hayleigh Collins, the Director and Head of Investor Relations. Thank you and you may proceed, Hayleigh.
Hayleigh Collins
Thank you. Good afternoon. And welcome to Taysha’s third quarter 2024 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the third quarter ended September 30, 2024. A copy of this press release is available on the company’s website and through our SEC filings.
Joining me on today’s call are Sean Nolan, Taysha’s CEO; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.
Please note that on today’s call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients’ dose-to-date in clinical trials to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the timing of initiating additional trials and reporting data from our clinical trials, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, the clinical potential of intrathecal administration and our current cash resources supporting our planned operating expenses and capital requirements into the fourth quarter of 2025.
These statements may include the expected timing and results of clinical trials for our product candidates and other clinical regulatory plans and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha’s growth, forecasted cash runway and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not historical facts or information.